Nalbuphine
- Generic Name
- Nalbuphine
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27NO4
- CAS Number
- 20594-83-6
- Unique Ingredient Identifier
- L2T84IQI2K
Overview
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Background
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Indication
For the relief of moderate to severe pain.
Associated Conditions
- Severe Pain
- Moderate Pain
- Obstetrical analgesia therapy
Clinical Trials
FDA Approved Products
Nalbuphine Hydrochloride
Manufacturer:Henry Schein, Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:20 mg in 1 mL
Approved: 2023/11/10
NDC:0404-9917
Nalbuphine Hydrochloride
Manufacturer:Henry Schein, Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:10 mg in 1 mL
Approved: 2023/11/10
NDC:0404-9918
Nalbuphine Hydrochloride
Manufacturer:Hospira, Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:20 mg in 1 mL
Approved: 2022/12/01
NDC:0409-1467
Nalbuphine Hydrochloride
Manufacturer:Hospira, Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:10 mg in 1 mL
Approved: 2022/12/01
NDC:0409-1463
Nalbuphine Hydrochloride
Manufacturer:Hospira, Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:20 mg in 1 mL
Approved: 2022/12/01
NDC:0409-1465
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath